Cover image for GLP-1 Pipeline Update: February 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-february-2025 Prime Therapeutics’...

Cover image for GLP-1 Pipeline Update: May 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-may-2025 Prime Therapeutics’ GLP-1...

Cover image for GLP-1 Pipeline Update: August 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-august-2025 Prime Therapeutics’ GLP-1...

cover image GLP-1 Pipeline Update: November 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-november-2025 Prime Therapeutics’ GLP-1...

cover image GLP-1 Pipeline Update: Feb 2026 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-february-2026 Prime Therapeutics’ GLP-1...

Cover image Quarterly view of the GLP-1 pipeline and anticipated indications. Prime Therapeutics /glp-1-pipeline-update-november-2024 Prime Therapeutics’ GLP-1 Pipeline Update focuses on the...

cover image Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-may-2026 Prime Therapeutics’ GLP-1 Pipeline Update focuses on the development...

Cover image Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-august-2026 Prime Therapeutics’ GLP-1 Pipeline Update focuses on the...

GLP-1 pipeline FAQs FDA-approved 2025 2027 Drug name/Manufacturer/Dosage form semaglutide 1.7 mg & 2.4 mg (Wegovy)/Novo Nordisk/SC DISCLAIMER The drug pipeline is fluid; the dates and information...

Drug name/Manufacturer/Dosage form retatrutide/Eli Lilly/SC Drug name/Manufacturer/Dosage form semaglutide (Wegovy)/Novo Nordisk/SC tirzepatide (Zepbound)/Eli Lilly/SC T2DM Access the complete...

Drug name/Manufacturer/Dosage form orforglipron/Eli Lilly/oral retatrutide/Eli Lilly/SC T2DM Diabetic nephropathy (prevention in pts with T2DM & CKD) Alzheimers disease Are generic versions of...

2027 OSA + obesity/overweight 2028 Drug name/Manufacturer/Dosage form retatrutide/Eli Lilly/SC survodutide/Zealand & Boehringer Ingelheim/SC 2026 Drug name/Manufacturer/Dosage form...

Drug name/Manufacturer/Dosage form semaglutide (Wegovy)/Novo Nordisk/SC - FDA decision 4Q2025 tirzepatide (Zepbound)/Eli Lilly/SC - FDA submission withdrawn Drug name/Manufacturer/Dosage form...

T2DM 2026 Diabetic nephropathy (prevention in pts with T2DM & CKD) T1DM + obesity or overweight Drug name/Manufacturer/Dosage form retatrutide/Eli Lilly/SC Drug name/Manufacturer/Dosage form...

Download our table OSA + obesity or overweight T2DM Drug name/Manufacturer/Dosage form dulaglutide (Trulicity)/Eli Lilly/SC liraglutide (Victoza)/Novo Nordisk/SC semaglutide 1 mg & 2 mg...

Drug name/Manufacturer/Dosage form retatrutide/Eli Lilly/SC Besides Novo Nordisk and Eli Lilly, what other pharmaceutical companies have GLP1s in the pipeline in late-stage development?...

Maryam Tabatabai, PharmD, vice president of clinical information, and Carole Kerzic, RPh, drug information pharmacist, share more about glucagon-like peptide-1 (GLP-1) receptor agonists in the drug...

New clinical publication from Prime Therapeutics explores the latest insights for GLP-1s, including trends in spend, drugs in the pipeline, management strategies and more

Check out the most recent indications for these popular medications to treat a growing range of conditions

In the latest episode of the “Pharmacy Friends” podcast, join health outcomes experts for a discussion about Prime’s industry-leading research into persistence and adherence of glucagon-like...

Leading GLP-1 persistence, adherence and clinical outcomes research helps inform health plans and members

Novo Nordisk’s semaglutide (Wegovy) recently received a U.S. Food and Drug Administration (FDA) accelerated approval for treating metabolic dysfunction-associated steatohepatitis (MASH), the first...

A paragraph is a self-contained unit of a discourse in writing dealing with a particular point or idea. Paragraphs are usually an expected part of formal writing, used to organize longer prose....

Dosage and administration In the VISIONARY trial, sibeprenlimab was administered SC at a dose of 400 mg every 4 weeks and can be self-administered. Place in therapy IgAN, also known as Berger’s...

Submitted supplemental drugs brensocatib oral Manufacturer: PTC Proposed indications Friedreich's ataxia (FA) Clinical overview Mechanism of action Vatiquinone is a first-in-class selective...

Year 2 Prime Therapeutics’ leading research shows 1 in 12 remain on a GLP-1 drug for obesity at three years. Findings also show improved persistence with high-potency, obesity-approved GLP-1...

publications Spring 2025 Prime Therapeutics Report March 21, 2025 The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. Our cover story (Page 18)...

publications The evolution of GLP-1s July 31, 2025 Prime's clinical experts share their perspectives on developing a holistic, individualized strategy to capitalize on opportunities and improve...

cover image for the 2025 Spring Prime Therapeutics Report Autoimmune management: Updates and challenges Prime Therapeutics /spring-2025-prime-therapeutics-report The Prime Therapeutics Report is...

New resource page offers the latest GLP-1 insights, research and perspectives

ensitrelvir - Infectious disease Name Manufacturer Clinical use Dosage form Development status - FDA designations FDA decision oxylanthanum carbonate (Renazorb) Unicycive Hyperphosphatemia (in...

Table view Editor-in-chief's message Year 2024 2025 2026 2027 2028 Projected Yearly U.S. Sales $0 $82 $177 $258 $311 The pipeline drug list is an aerial outline of drugs with anticipated FDA...

Maryam Tabatabai, PharmD, associate vice president of clinical information, offers predictions about forthcoming drug approvals, the latest on a new voucher pilot, updated biosimilar guidance and more

Name Manufacturer Clinical use Dosage form Development status - FDA designations FDA decision aflibercept (Eylea HD) 8 mg Regeneron Macular edema from RVO (8 mg dose) Intravitreal sNDA – PR Oct-Dec...

Configure the table properties Dosage and administration In the Phase 3 VALOR clinical trial, brepocitinib was administered orally once daily at a dose of 15 mg or 30 mg for 52 weeks. Place in...

denecimig (Mim8) - Hematologic The Deep dive section features an analysis for select pipeline drugs that are expected to be FDA-approved in the upcoming quarters. Selected agents are expected to...

In the latest episode of the “Pharmacy Friends” podcast, hear more from Prime Therapeutics experts about how oral glucagon-like peptide-1 (GLP-1) agonist medications may transform the treatment...

Following real-world analysis of GLP-1 drugs for weight loss, Prime/Magellan Rx releases new video about GLP-1 research

New report details the latest on GLP-1s